細菌ワクチンの世界市場

細菌ワクチンの世界市場は2030年までに358億米ドルに到達

2024年に249億米ドルと推定される細菌ワクチンの世界市場は、分析期間2024-2030年にCAGR 6.2%で成長し、2030年には358億米ドルに達すると予測されます。百日咳/百日咳ワクチンは、本レポートで分析したセグメントの1つであり、CAGRは5.0%を記録し、分析期間終了時には92億米ドルに達すると予測されます。その他のワクチンタイプ分野の成長率は、分析期間中CAGR 4.5%と推定されます。

米国市場は68億米ドルと推定、中国はCAGR 9.6％で成長予測

米国の細菌ワクチン市場は、2024年に68億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに72億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.2％と6.0％と予測されています。欧州では、ドイツがCAGR 4.1%で成長すると予測されています。

世界の細菌ワクチン市場- 主要動向と促進要因のまとめ

なぜ細菌ワクチンが感染症対策、抗菌薬耐性緩和、世界保健準備の戦略的資産として再浮上しているのか？

世界の保健システムが抗菌薬耐性（AMR）の増加、ワクチンで予防可能な疾病の復活、流行しやすい病原体に対する継続的な脆弱性に直面する中、細菌ワクチンは再び注目を集めています。これらのワクチンは、罹患率と死亡率を予防すると同時に、経験的な抗菌薬治療がしばしば必要となる細菌感染症の発生率を低下させることで、間接的に抗生物質の過剰使用を抑制するという二重の役割を担っています。世界のAMRの危機に対する懸念が高まる中、細菌予防接種は、細菌による疾病負担を軽減し、抗生物質の有効性を維持するための最前線の戦略として、ますます認識されるようになってきています。

肺炎球菌、髄膜炎菌、インフルエンザ菌b型（Hib）、百日咳菌のような病原体が脅威を与え続けていることは、細菌ワクチンプログラムの永続的な重要性を強調しています。地政学的な不安定さ、ワクチン接種のためらい、医療システムの混乱などが原因で、ワクチン接種率が低下し、地域や地方でアウトブレイクが発生しているため、定期予防接種のインフラ整備やブースター・キャンペーンへの新たな投資が促されています。細菌感染症は乳幼児、高齢者、免疫不全集団に不釣り合いな影響を及ぼすため、世界の公衆衛生当局は、これらのワクチンをライフコース予防接種の枠組みに組み込もうとしています。

同時に、新たな人獣共通感染症や薬剤耐性菌の脅威が研究開発の勢いを加速させ、世界のワクチン戦略を再構築しています。現在、各国政府や超国家機関は、細菌ワクチンの備蓄や対象を絞った展開計画を、より広範なパンデミック対策の枠組みに組み込もうとしています。これは、反応的な公衆衛生態勢から予防的な公衆衛生態勢への移行を示すものであり、細菌ワクチンを疾病予防の手段としてだけでなく、世界な保健安全保障基盤の不可欠な要素として位置づけています。

コンジュゲート技術、タンパク質サブユニットプラットフォーム、およびアジュバントイノベーションは、ワクチンの有効性と接種率をどのように向上させているのか？

結合型ワクチン技術は、多糖類抗原をタンパク質キャリアに結合させることで、カプセル化された細菌に対する免疫原性を大幅に改善し、より強力で持続性の高い免疫応答を引き出しています。例えば、肺炎球菌結合型ワクチン（PCV）は、小児における侵襲性肺炎球菌疾患を劇的に減少させ、集団全体に群衆免疫を付与しています。ロジスティックスを簡素化し、ヘルスケアシステムの負担を軽減しながら、予防効果を高めるために、血清型の適用範囲を拡大し、スケジュールを最適化することに現在も取り組んでいます。

タンパク質サブユニットワクチンは、多糖体をベースとするアプローチが有効でない病原体に対して普及しつつあります。精製された細菌タンパク質やトキソイドを含むこれらの製剤は、強力な安全性プロファイルとともに標的免疫応答を提供します。百日咳ワクチン、ジフテリアワクチン、破傷風ワクチンなどがその主な例であり、新しい候補では、菌株のカバー範囲を広げ、抗原ドリフトに対処するために、保存されたタンパク質抗原を探索しています。また、新たに出現した変異型に対応してサブユニット製剤を迅速に変更できるようになったことで、パンデミック（世界的大流行）の状況におけるワクチンの重要性も高まっています。

アジュバントの技術革新は、特に高齢者や免疫学的に課題のある人々における細菌ワクチンの性能をさらに向上させています。AS01、MF59、CpGオリゴデオキシヌクレオチドなどの新しいアジュバントは、細胞性免疫や体液性免疫を増強し、用量を節約し、交差防御応答を生成するために組み込まれています。これらの進歩は、持続的な有効性、反応原性の低減、より広範な集団への有効性を有する次世代の細菌ワクチンを開発する上で、特に成人免疫市場やブースター免疫市場の拡大という状況において極めて重要です。

細菌ワクチン接種プログラムの需要を形成しているのは、どのような対象集団、疾病の優先順位、政策要因か？

特に髄膜炎、肺炎、敗血症、百日咳の早期予防を優先する国の予防接種プログラムでは、小児人口が依然として主要な接種対象です。乳幼児期にHib、DTP、PCVを広く接種することで、特に低・中所得国（LMICs）において、世界の子どもの死亡率は劇的に減少しました。しかし、ワクチンへのアクセスにおける格差やサプライチェーンの制限は、ワクチン摂取に影響を与え続けており、GAVIとWHOは、段階的価格設定とプール調達を通じて公平性と購入しやすさを改善する努力を続けています。

高齢者や慢性合併症を持つ人は、細菌性肺炎や菌血症、院内感染にかかりやすいため、対象者が拡大しています。肺炎球菌、ジフテリア・破傷風・百日咳（Tdap）、髄膜炎菌ブースターを含む成人予防接種戦略は、高齢者集団のヘルスケア負担を軽減し、質調整生存年を改善するために、高所得国や一部のLMICで採用されています。インフルエンザワクチンやCOVID-19ワクチンとの季節的同時接種戦略も、接種の効率化と接種率の向上を目指して評価中です。

国の予防接種スケジュール改定からAMR緩和計画まで、政策イニシアチブが細菌ワクチンのスケールアップへの機関投資や商業投資を促進しています。各国政府は、疾病サーベイランスの強化、キャッチアップキャンペーンの実施、高感染地域におけるリスクに応じた予防接種の実施などを進めています。これと並行して、渡航医療、軍の健康プログラム、アウトブレイク対応プロトコルでは、先制的対策として細菌ワクチンが取り入れられています。このような動きにより、細菌ワクチンは公衆衛生、緊急事態への備え、慢性疾患管理の各領域を横断するツールとして、その役割が強化されつつあります。

世界サプライチェーン投資、多価製剤、規制革新はどのように市場成長を加速させているか？

世界な製造とコールドチェーンインフラへの戦略的投資により、特にこれまでデリバリー上の制約が適用範囲を制限してきたLMICsにおいて、細菌ワクチンへのアクセス拡大が可能になりつつあります。官民パートナーシップ、先進的な市場コミットメント、技術移転協定は、地域のワクチン生産ハブを活性化し、集中供給への依存を減らし、流通のタイムラインを短縮しています。このような投資はまた、保健上の緊急事態や地政学的混乱時の供給ショックに対する回復力を高めています。

多価製剤への移行は、予防接種スケジュールを合理化し、コスト効率を向上させる。複数の細菌性病原体を標的とする混合ワクチン（5価や6価製剤など）は、注射の負担を軽減し、コンプライアンスを向上させるため、小児科プログラムで広く採用されています。特に肺炎球菌、腸チフス菌、淋菌のように抗原の多様性がワクチン設計を複雑にしている病原体に対しては、1つの細菌種で複数の菌株を標的とする広域スペクトル候補の開発にも取り組んでいます。

規制の枠組みは、安全性や有効性を損なうことなく、ワクチン開発と展開を迅速化するために進化しています。適応試験デザイン、実臨床エビデンスの統合、および迅速承認は、パンデミック対応型および日常使用型ワクチンの市場投入までの時間を短縮するために使用されています。WHOの事前承認プログラムと地域的な規制調和への取り組みも、特に十分なサービスを受けていない人々や世界ヘルス上の優先事項を対象とした製品の市場参入経路を強化しています。

長期的な市場戦略において、パンデミック対策、AMR緩和、新規ターゲット拡大はどのような役割を果たすのか？

細菌ワクチンエルシニア・ペスティス（Yersinia pestis）、バークホルデリア・シュードマレイ（Burkholderia pseudomallei）、クロストリジオイデス・ディフィシル（Clostridioides difficile）など、流行する可能性のある病原体を中心に、パンデミック対策戦略の重要な要素として台頭してきています。一方、多国間機関は、ワンヘルスアプローチの下で、ヒト、動物、環境の健康リスクを関連付けたワクチンの優先順位付けの枠組みを開発しています。

AMRと闘う世界の取り組みが強化される中、ワクチンは抗生物質への依存を減らし、耐性菌の発生を遅らせるための上流の介入として位置づけられています。ワクチン接種は、抗生物質を必要とする一次感染を予防し、間接的に抗菌薬への曝露と耐性のプレッシャーを軽減します。このような役割は、AMR国家行動計画において認識されつつあり、現在では臨床と地域社会の両方の環境における測定可能な目標として、細菌ワクチンの接種率が含まれています。

細菌ワクチンのパイプラインは、ヘリコバクターピロリ、大腸菌（尿路病原性株および腸毒素原性株）、赤痢菌、アシネトバクターバウマニーなどの院内感染病原体といったアンメットニーズに対応するために拡大しつつあります。こうした取り組みは、従来の小児用ワクチンから、成人用、旅行用、院内感染予防の市場へと戦略的に軸足を移していることを反映しています。鼻腔内、経口、mRNAをベースとしたものなど、新しいデリバリープラットフォームが開発中であり、さまざまな人口層における有効性、利用しやすさ、受容性を高めています。

細菌ワクチン市場の成長を促進する要因は何ですか？

細菌ワクチン市場は、公衆衛生上の必要性、抗菌薬スチュワードシップ、国際的な安全保障が融合し、風土病や新興の脅威に対する戦略的介入として予防接種を高めるにつれて成長しています。需要は、小児期の予防にとどまらず、成人、旅行、院内ケアの場面にも拡大しています。

主な成長要因としては、AMRに対する意識の高まり、予防接種ガイドラインの拡大、結合型およびタンパク質サブユニットプラットフォームの技術的進歩、公平なアクセスとコールドチェーンインフラへの継続的投資などが挙げられます。パイプラインの多様化、政策の調整、ウイルス性ワクチンとの共同投与による相乗効果が、長期的な勢いを強めています。

抗生物質疲労と健康リスクの世界化の時代において、細菌性病原体がその関連性を再認識する中、ワクチンは、公衆衛生のツールとしてだけでなく、ポスト抗生物質時代における全身的な回復力の精密機器として、感染症対策の未来を再定義することができるのだろうか？

セグメント

ワクチンの種類（百日咳/百日せきワクチン、破傷風ワクチン、ジフテリアワクチン、肺炎球菌ワクチン、髄膜炎菌ワクチン、腸チフスワクチン、結核菌ワクチン、コレラワクチン、充血性腸炎ワクチン、その他のワクチン）、患者の年齢層（小児用ワクチン、青少年用ワクチン、成人用ワクチン、老年用ワクチン）、投与経路（筋肉内投与、静脈内投与、皮下投与、その他の投与経路）、販売チャネル（公的、私的）

調査対象企業の例（合計 37注目の企業）

• Astellas Pharma Inc.
• AstraZeneca plc
• Bavarian Nordic
• Bharat Biotech
• Biological E. Limited
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• CSL Limited（Seqirus）
• Daiichi Sankyo Company, Limited
• Emergent BioSolutions Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc（GSK）
• Indian Immunologicals Ltd.
• Johnson & Johnson
• KM Biologics Co., Ltd.
• LG Chem Ltd.
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Mylan N.V.
• Novartis AG

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Bacterial Vaccines Market to Reach US$35.8 Billion by 2030

The global market for Bacterial Vaccines estimated at US$24.9 Billion in the year 2024, is expected to reach US$35.8 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Pertussis / Whooping Cough Vaccines, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$9.2 Billion by the end of the analysis period. Growth in the Other Vaccine Types segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.8 Billion While China is Forecast to Grow at 9.6% CAGR

The Bacterial Vaccines market in the U.S. is estimated at US$6.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.2 Billion by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Bacterial Vaccines Market - Key Trends & Drivers Summarized

Why Are Bacterial Vaccines Re-Emerging as Strategic Assets in Infectious Disease Control, Antimicrobial Resistance Mitigation, and Global Health Preparedness?

Bacterial vaccines are regaining prominence as global health systems confront rising antimicrobial resistance (AMR), resurgence of vaccine-preventable diseases, and ongoing vulnerability to epidemic-prone pathogens. These vaccines play a dual role in preventing morbidity and mortality while indirectly curbing antibiotic overuse by reducing the incidence of bacterial infections that often prompt empirical antimicrobial treatment. Amid growing concern over the global AMR crisis, bacterial immunization is increasingly recognized as a frontline strategy for reducing bacterial disease burden and preserving antibiotic efficacy.

The continued threat posed by pathogens such as Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae type b (Hib), and Bordetella pertussis underscores the enduring importance of bacterial vaccine programs. Vaccination coverage gaps-driven by geopolitical instability, vaccine hesitancy, and health system disruptions-have led to local and regional outbreaks, prompting renewed investments in routine immunization infrastructure and booster campaigns. As bacterial infections disproportionately affect infants, the elderly, and immunocompromised populations, these vaccines are being integrated into life-course immunization frameworks by global public health authorities.

Simultaneously, emerging zoonotic and drug-resistant bacterial threats are accelerating R&D momentum and reshaping global vaccine strategies. Governments and supranational agencies are now incorporating bacterial vaccine stockpiles and targeted rollout plans into broader pandemic preparedness frameworks. This marks a shift from reactive to preventive public health postures, positioning bacterial vaccines not only as tools of disease prevention but also as essential elements of global health security infrastructure.

How Are Conjugate Technologies, Protein Subunit Platforms, and Adjuvant Innovation Advancing Vaccine Efficacy and Coverage?

Conjugate vaccine technologies have significantly improved immunogenicity against encapsulated bacteria by linking polysaccharide antigens to protein carriers, eliciting stronger and longer-lasting immune responses. Pneumococcal conjugate vaccines (PCVs), for example, have dramatically reduced invasive pneumococcal disease in children and conferred herd immunity across populations. Ongoing efforts are focused on expanding serotype coverage and optimizing schedules to enhance protection while simplifying logistics and reducing healthcare system burdens.

Protein subunit vaccines are gaining traction for pathogens where polysaccharide-based approaches are less effective. These formulations, which include purified bacterial proteins or toxoids, offer targeted immune responses with strong safety profiles. Pertussis, diphtheria, and tetanus vaccines are key examples, and newer candidates are exploring conserved protein antigens to broaden strain coverage and address antigenic drift. The ability to rapidly modify subunit formulations in response to emerging variants is also strengthening their relevance in pandemic contexts.

Adjuvant innovation is further enhancing bacterial vaccine performance, particularly in older adults and immunologically challenged individuals. Novel adjuvants-such as AS01, MF59, and CpG oligodeoxynucleotides-are being incorporated to boost cellular and humoral immunity, improve dose-sparing, and generate cross-protective responses. These advances are critical for developing next-generation bacterial vaccines with durable efficacy, reduced reactogenicity, and broader population reach, especially in the context of expanding adult and booster immunization markets.

Which Target Populations, Disease Priorities, and Policy Drivers Are Shaping Demand for Bacterial Vaccination Programs?

Pediatric populations remain the core recipients of bacterial vaccines, particularly in national immunization programs that prioritize early protection against meningitis, pneumonia, sepsis, and pertussis. Widespread administration of Hib, DTP, and PCV in infancy has dramatically reduced global child mortality, especially in low- and middle-income countries (LMICs). However, disparities in access and supply chain limitations continue to influence vaccine uptake, driving efforts by Gavi and WHO to improve equity and affordability through tiered pricing and pooled procurement.

Elderly adults and individuals with chronic comorbidities are an expanding target group due to their heightened susceptibility to bacterial pneumonia, bacteremia, and hospital-acquired infections. Adult immunization strategies-including pneumococcal, diphtheria-tetanus-pertussis (Tdap), and meningococcal boosters-are being adopted by high-income nations and select LMICs to reduce healthcare burden and improve quality-adjusted life years (QALYs) among aging populations. Seasonal co-administration strategies with influenza or COVID-19 vaccines are also under evaluation to streamline delivery and improve coverage.

Policy initiatives-ranging from national immunization schedule revisions to AMR mitigation plans-are driving institutional and commercial investment in bacterial vaccine scale-up. Governments are strengthening disease surveillance, catch-up campaigns, and risk-based immunization in high-transmission zones. In parallel, travel medicine, military health programs, and outbreak response protocols are incorporating bacterial vaccines as pre-emptive measures. These dynamics are reinforcing the role of bacterial vaccines as cross-cutting tools across public health, emergency preparedness, and chronic disease management domains.

How Are Global Supply Chain Investments, Multivalent Formulations, and Regulatory Innovation Accelerating Market Growth?

Strategic investments in global manufacturing and cold-chain infrastructure are enabling expanded access to bacterial vaccines, particularly in LMICs where delivery constraints have historically limited coverage. Public-private partnerships, advanced market commitments, and tech-transfer agreements are catalyzing regional vaccine production hubs to reduce reliance on centralized supply and shorten distribution timelines. These investments are also fostering greater resilience against supply shocks during health emergencies or geopolitical disruptions.

The push toward multivalent formulations is streamlining immunization schedules and improving cost-efficiency. Combination vaccines targeting multiple bacterial pathogens-such as pentavalent and hexavalent formulations-are being widely adopted in pediatric programs to reduce injection burden and improve compliance. Development efforts are also underway for broad-spectrum candidates that target multiple strains within a single bacterial species, particularly for pathogens like Streptococcus pneumoniae, Salmonella typhi, and Neisseria gonorrhoeae where antigenic diversity complicates vaccine design.

Regulatory frameworks are evolving to expedite vaccine development and rollout without compromising safety or efficacy. Adaptive trial designs, real-world evidence integration, and fast-track approvals are being used to accelerate time-to-market for both pandemic-responsive and routine-use bacterial vaccines. The WHO prequalification program and regional regulatory harmonization efforts are also enhancing market entry pathways, especially for products targeting underserved populations and global health priorities.

What Role Do Pandemic Preparedness, AMR Mitigation, and Novel Target Expansion Play in Long-Term Market Strategy?

Bacterial vaccines are emerging as critical components of pandemic preparedness strategies, with a focus on pathogens with epidemic potential such as Yersinia pestis, Burkholderia pseudomallei, and Clostridioides difficile. Government funding mechanisms and biodefense programs are supporting R&D for these high-risk agents, while multilateral organizations are developing vaccine prioritization frameworks under the One Health approach-linking human, animal, and environmental health risks.

As global efforts to combat AMR intensify, vaccines are being positioned as upstream interventions to reduce antibiotic reliance and slow resistance development. Vaccination prevents primary infections that would otherwise require antibiotics, indirectly reducing antimicrobial exposure and resistance pressure. This role is gaining recognition in AMR national action plans, which now include bacterial immunization coverage as a measurable objective in both clinical and community settings.

The bacterial vaccine pipeline is expanding to address unmet needs such as Helicobacter pylori, Escherichia coli (for uropathogenic and enterotoxigenic strains), Shigella, and hospital-acquired pathogens like Acinetobacter baumannii. These efforts reflect a broader strategic pivot from traditional childhood vaccines toward adult, travel, and nosocomial prevention markets. Novel delivery platforms-including intranasal, oral, and mRNA-based bacterial vaccines-are under development to enhance efficacy, accessibility, and acceptance in varied population segments.

What Are the Factors Driving Growth in the Bacterial Vaccines Market?

The bacterial vaccines market is growing as public health imperatives, antimicrobial stewardship, and global health security converge to elevate immunization as a strategic intervention against both endemic and emerging threats. Demand is expanding beyond childhood prevention into adult, travel, and nosocomial care settings.

Key growth drivers include rising AMR awareness, expanded immunization guidelines, technological advancements in conjugate and protein subunit platforms, and ongoing investments in equitable access and cold-chain infrastructure. Pipeline diversification, policy alignment, and co-administration synergies with viral vaccines are reinforcing long-term momentum.

As bacterial pathogens reassert their relevance in an era of antibiotic fatigue and globalized health risks, could vaccines redefine the future of infectious disease control-not just as public health tools, but as precision instruments of systemic resilience in the post-antibiotic age?

SCOPE OF STUDY:

The report analyzes the Bacterial Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vaccine Type (Pertussis / Whooping Cough Vaccines, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines, Shigellosis Vaccines, Other Vaccine Types); Patient Age Group (Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines, Geriatric Vaccines); Administration Route (Intramuscular, Intravenous, Subcutaneous, Other Administration Routes); Distribution Channel (Public, Private)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

• Astellas Pharma Inc.
• AstraZeneca plc
• Bavarian Nordic
• Bharat Biotech
• Biological E. Limited
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• CSL Limited (Seqirus)
• Daiichi Sankyo Company, Limited
• Emergent BioSolutions Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc (GSK)
• Indian Immunologicals Ltd.
• Johnson & Johnson
• KM Biologics Co., Ltd.
• LG Chem Ltd.
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Mylan N.V.
• Novartis AG

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Bacterial Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Antibiotic-Resistant Infections Throws the Spotlight on Bacterial Vaccines
  • Growth in Immunization Programs Against Meningococcal, Pneumococcal, and Pertussis Infections Spurs Market Expansion
  • OEM Innovation in Conjugate and Recombinant Protein Vaccines Enhances Immunogenicity and Safety Profiles
  • Increased Demand for Adult and Geriatric Immunization Supports Expansion Beyond Pediatric Coverage
  • Use of mRNA and DNA Technologies for Bacterial Targets Accelerates Development Timelines
  • Public-Private Partnerships Drive Clinical Trials and Global Access to High-Priority Vaccines
  • Integration With National Immunization Registries Supports Dose Scheduling and Adherence
  • OEMs Targeting Multivalent and Combination Formulations Improve Compliance and Delivery Efficiency
  • Rise in Antimicrobial Stewardship Programs Encourages Vaccine-Driven Infection Control Strategies
  • Emerging Threats Like C. difficile and H. pylori Infection Spur Niche Vaccine Pipeline Growth
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Bacterial Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Bacterial Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Bacterial Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Bacterial Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Pertussis / Whooping Cough Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Pertussis / Whooping Cough Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Pertussis / Whooping Cough Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Other Vaccine Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Tetanus Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Tetanus Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Tetanus Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Diphtheria Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Diphtheria Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Diphtheria Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Pneumococcal Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Pneumococcal Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Pneumococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Meningococcal Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Meningococcal Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Meningococcal Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Typhoid Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Typhoid Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Typhoid Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Tuberculosis Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Tuberculosis Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Tuberculosis Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Cholera Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Cholera Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Cholera Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Shigellosis Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Shigellosis Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Shigellosis Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Pediatric Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Pediatric Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Pediatric Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Adolescent Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Adolescent Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Adolescent Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Adult Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Adult Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Adult Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Geriatric Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Geriatric Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Geriatric Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Intramuscular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Intramuscular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Intravenous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Intravenous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Subcutaneous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Subcutaneous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 59: World Recent Past, Current & Future Analysis for Public by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 60: World Historic Review for Public by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: World 15-Year Perspective for Public by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 62: World Recent Past, Current & Future Analysis for Private by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 63: World Historic Review for Private by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: World 15-Year Perspective for Private by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 65: USA Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: USA 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 68: USA Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: USA Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: USA 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 71: USA Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: USA Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: USA 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 74: USA Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: USA Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: USA 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Canada 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 80: Canada Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Canada Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Canada 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 83: Canada Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Canada Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Canada 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 86: Canada Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Canada Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Canada 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• JAPAN
  • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Japan 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 92: Japan Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Japan Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Japan 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 95: Japan Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Japan Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Japan 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 98: Japan Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Japan Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Japan 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• CHINA
  • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 101: China Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: China Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: China 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 104: China Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: China Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: China 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 107: China Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: China Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: China 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 110: China Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: China Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: China 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• EUROPE
  • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Bacterial Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Bacterial Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Europe 15-Year Perspective for Bacterial Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Europe Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Europe 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 119: Europe Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Europe Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Europe 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 122: Europe Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Europe Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Europe 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 125: Europe Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Europe Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Europe 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• FRANCE
  • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 128: France Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: France Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: France 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 131: France Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: France Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: France 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 134: France Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: France Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: France 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 137: France Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: France Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: France 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• GERMANY
  • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 140: Germany Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Germany Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Germany 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 143: Germany Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Germany Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Germany 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 146: Germany Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Germany Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Germany 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 149: Germany Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Germany Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Germany 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 152: Italy Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Italy Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Italy 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 155: Italy Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Italy Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Italy 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 158: Italy Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Italy Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Italy 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 161: Italy Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Italy Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Italy 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 164: UK Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: UK Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: UK 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 167: UK Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: UK Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: UK 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 170: UK Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: UK Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: UK 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 173: UK Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: UK Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: UK 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 176: Spain Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Spain Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Spain 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 179: Spain Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Spain Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Spain 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 182: Spain Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Spain Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Spain 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 185: Spain Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Spain Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Spain 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 188: Russia Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Russia Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Russia 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 191: Russia Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Russia Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Russia 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 194: Russia Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Russia Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Russia 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 197: Russia Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Russia Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Russia 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Europe Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Europe 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Europe Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Europe 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 206: Rest of Europe Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Europe Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Europe 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 209: Rest of Europe Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Europe Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Rest of Europe 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Bacterial Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Bacterial Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 15-Year Perspective for Bacterial Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Asia-Pacific Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Asia-Pacific 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Asia-Pacific Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Asia-Pacific 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 221: Asia-Pacific Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Asia-Pacific Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Asia-Pacific 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 224: Asia-Pacific Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Asia-Pacific Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Asia-Pacific 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 227: Australia Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Australia Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Australia 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 230: Australia Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Australia Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Australia 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 233: Australia Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Australia Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Australia 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 236: Australia Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Australia Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Australia 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• INDIA
  • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 239: India Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: India Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: India 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 242: India Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: India Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: India 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 245: India Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: India Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: India 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 248: India Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: India Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: India 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 251: South Korea Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: South Korea Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: South Korea 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 254: South Korea Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: South Korea Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: South Korea 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 257: South Korea Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: South Korea Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: South Korea 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 260: South Korea Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: South Korea Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: South Korea 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Rest of Asia-Pacific Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Rest of Asia-Pacific 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Rest of Asia-Pacific Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Rest of Asia-Pacific 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 269: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Rest of Asia-Pacific Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Rest of Asia-Pacific 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 272: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Rest of Asia-Pacific Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Rest of Asia-Pacific 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Bacterial Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Bacterial Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Latin America 15-Year Perspective for Bacterial Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 278: Latin America Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Latin America Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Latin America 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 281: Latin America Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Latin America Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Latin America 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 284: Latin America Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Latin America Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Latin America 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 287: Latin America Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Latin America Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Latin America 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 290: Argentina Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Argentina Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Argentina 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 293: Argentina Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Argentina Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Argentina 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 296: Argentina Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Argentina Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Argentina 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 299: Argentina Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Argentina Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Argentina 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 302: Brazil Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Brazil Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Brazil 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 305: Brazil Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Brazil Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Brazil 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 308: Brazil Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Brazil Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Brazil 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 311: Brazil Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Brazil Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Brazil 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 314: Mexico Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Mexico Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Mexico 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 317: Mexico Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Mexico Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Mexico 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 320: Mexico Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Mexico Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Mexico 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 323: Mexico Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Mexico Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Mexico 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Rest of Latin America Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Rest of Latin America 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Rest of Latin America Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Rest of Latin America 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 332: Rest of Latin America Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Rest of Latin America Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Rest of Latin America 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 335: Rest of Latin America Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Rest of Latin America Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Rest of Latin America 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Bacterial Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Bacterial Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Middle East 15-Year Perspective for Bacterial Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 341: Middle East Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Middle East Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Middle East 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 344: Middle East Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Middle East Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Middle East 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 347: Middle East Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Middle East Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Middle East 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 350: Middle East Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Middle East Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Middle East 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 353: Iran Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Iran Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Iran 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 356: Iran Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Iran Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Iran 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 359: Iran Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Iran Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Iran 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 362: Iran Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Iran Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Iran 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 365: Israel Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Israel Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Israel 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 368: Israel Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Israel Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Israel 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 371: Israel Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Israel Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Israel 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 374: Israel Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Israel Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Israel 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Saudi Arabia Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Saudi Arabia 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Saudi Arabia Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Saudi Arabia 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 383: Saudi Arabia Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Saudi Arabia Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Saudi Arabia 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 386: Saudi Arabia Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Saudi Arabia Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Saudi Arabia 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 389: UAE Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: UAE Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: UAE 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 392: UAE Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: UAE Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: UAE 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 395: UAE Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: UAE Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: UAE 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 398: UAE Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: UAE Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: UAE 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Rest of Middle East Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Rest of Middle East 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Rest of Middle East Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Rest of Middle East 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 407: Rest of Middle East Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Rest of Middle East Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 409: Rest of Middle East 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 410: Rest of Middle East Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Rest of Middle East Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 412: Rest of Middle East 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030
• AFRICA
  • Bacterial Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 413: Africa Recent Past, Current & Future Analysis for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Africa Historic Review for Bacterial Vaccines by Vaccine Type - Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 415: Africa 15-Year Perspective for Bacterial Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Pertussis / Whooping Cough Vaccines, Other Vaccine Types, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis Vaccines, Cholera Vaccines and Shigellosis Vaccines for the Years 2015, 2025 & 2030
  • TABLE 416: Africa Recent Past, Current & Future Analysis for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Africa Historic Review for Bacterial Vaccines by Patient Age Group - Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 418: Africa 15-Year Perspective for Bacterial Vaccines by Patient Age Group - Percentage Breakdown of Value Sales for Pediatric Vaccines, Adolescent Vaccines, Adult Vaccines and Geriatric Vaccines for the Years 2015, 2025 & 2030
  • TABLE 419: Africa Recent Past, Current & Future Analysis for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 420: Africa Historic Review for Bacterial Vaccines by Administration Route - Intramuscular, Intravenous, Subcutaneous and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 421: Africa 15-Year Perspective for Bacterial Vaccines by Administration Route - Percentage Breakdown of Value Sales for Intramuscular, Intravenous, Subcutaneous and Other Administration Routes for the Years 2015, 2025 & 2030
  • TABLE 422: Africa Recent Past, Current & Future Analysis for Bacterial Vaccines by Distribution Channel - Public and Private - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 423: Africa Historic Review for Bacterial Vaccines by Distribution Channel - Public and Private Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 424: Africa 15-Year Perspective for Bacterial Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public and Private for the Years 2015, 2025 & 2030

IV. COMPETITION